Estrella Immunopharma Statistics
Total Valuation
ESLA has a market cap or net worth of $53.55 million. The enterprise value is $51.75 million.
Important Dates
The next estimated earnings date is Tuesday, March 4, 2025, after market close.
| Earnings Date | Mar 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ESLA has 36.18 million shares outstanding. The number of shares has increased by 6,450.97% in one year.
| Current Share Class | 36.18M |
| Shares Outstanding | 36.18M |
| Shares Change (YoY) | +6,450.97% |
| Shares Change (QoQ) | -0.87% |
| Owned by Insiders (%) | 2.70% |
| Owned by Institutions (%) | 0.81% |
| Float | 9.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 71.75 |
| P/TBV Ratio | 71.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.75, with a Debt / Equity ratio of 0.01.
| Current Ratio | 0.75 |
| Quick Ratio | 0.60 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -163.06% and return on invested capital (ROIC) is -98.90%.
| Return on Equity (ROE) | -163.06% |
| Return on Assets (ROA) | -35.45% |
| Return on Invested Capital (ROIC) | -98.90% |
| Return on Capital Employed (ROCE) | -1,181.36% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ESLA has paid $1,625 in taxes.
| Income Tax | 1,625 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +39.62% in the last 52 weeks. The beta is 0.41, so ESLA's price volatility has been lower than the market average.
| Beta (5Y) | 0.41 |
| 52-Week Price Change | +39.62% |
| 50-Day Moving Average | 1.19 |
| 200-Day Moving Average | 1.12 |
| Relative Strength Index (RSI) | 67.10 |
| Average Volume (20 Days) | 91,357 |
Short Selling Information
The latest short interest is 10,367, so 0.03% of the outstanding shares have been sold short.
| Short Interest | 10,367 |
| Short Previous Month | 14,494 |
| Short % of Shares Out | 0.03% |
| Short % of Float | 0.10% |
| Short Ratio (days to cover) | 0.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -8.82M |
| Pretax Income | -6.09M |
| Net Income | -8.82M |
| EBITDA | n/a |
| EBIT | -8.82M |
| Earnings Per Share (EPS) | -$0.25 |
Full Income StatementBalance Sheet
The company has $1.80 million in cash and $4,000 in debt, giving a net cash position of $1.79 million or $0.05 per share.
| Cash & Cash Equivalents | 1.80M |
| Total Debt | 4,000 |
| Net Cash | 1.79M |
| Net Cash Per Share | $0.05 |
| Equity (Book Value) | 746,286 |
| Book Value Per Share | 0.02 |
| Working Capital | -753,714 |
Full Balance SheetCash Flow
| Operating Cash Flow | -18.01M |
| Capital Expenditures | n/a |
| Free Cash Flow | -18.01M |
| FCF Per Share | -$0.50 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |